Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 14/20 | 1.00 |
| ▸ | JAK2 | O60674 | 8/20 | 1.00 |
| ▸ | AURKA | O14965 | 4/20 | 1.00 |
| ▸ | JAK3 | P52333 | 3/20 | 1.00 |
| ▸ | FGFR1 | P11362 | 3/20 | 1.00 |
| ▸ | FLT3 | P36888 | 3/20 | 1.00 |
| ▸ | PTK2 | Q05397 | 3/20 | 1.00 |
| ▸ | NTRK3 | Q16288 | 2/20 | 1.00 |
| ▸ | NTRK2 | Q16620 | 2/20 | 1.00 |
| ▸ | BTK | Q06187 | 2/20 | 1.00 |
| ▸ | ALK | Q9UM73 | 2/20 | 1.00 |
| ▸ | RET | P07949 | 2/20 | 1.00 |
| ▸ | TNK2 | Q07912 | 2/20 | 1.00 |
| ▸ | LCK | P06239 | 1/20 | 1.00 |
| ▸ | FYN | P06241 | 1/20 | 1.00 |
| ▸ | IGF1R | P08069 | 1/20 | 1.00 |
| ▸ | FLT1 | P17948 | 1/20 | 1.00 |
| ▸ | LTK | P29376 | 1/20 | 1.00 |
| ▸ | KDR | P35968 | 1/20 | 1.00 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20626754 | 1.00 | NTRK1 (1.00) | NTRK1JAK2AURKAJAK3FGFR1 | |
| SCHEMBL18281508 | 0.84 | NTRK1 (0.73) | NTRK1JAK2AURKAJAK3FGFR1 | |
| SCHEMBL31060183 | 0.84 | NTRK1 (0.73) | NTRK1JAK2AURKAJAK3FGFR1 | |
| SCHEMBL588730 | 0.84 | NTRK1 (0.73) | NTRK1JAK2AURKAJAK3FGFR1 | |
| SCHEMBL29434985 | 0.84 | NTRK1 (0.73) | NTRK1JAK2AURKAJAK3FGFR1 | |
| SCHEMBL23217067 | 0.81 | NTRK1 (0.80) | NTRK1JAK2AURKAJAK3FGFR1 | |
| SCHEMBL29794572 | 0.81 | NTRK1 (0.80) | NTRK1JAK2AURKAJAK3FGFR1 | |
| SCHEMBL3340493 | 0.81 | NTRK1 (0.80) | NTRK1JAK2AURKAJAK3FGFR1 | |
| Phosphoric Acid SCHEMBL3041888 | 0.80 | NTRK1 (0.66) | NTRK1JAK2AURKAJAK3FGFR1 | |
| SCHEMBL3033142 | 0.80 | NTRK1 (0.78) | NTRK1JAK2AURKAJAK3FGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 146 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025216949-A1 | METHODS FOR TREATING A TUMOR WITH ANTI-CDH6 ANTIBODY DRUG CONJUGATES | ONCUSP THERAPEUTICS, INC. (US) | 2025-10-16 | — | — | WO | claimed |
| US-20250129429-A1 | GENE FUSIONS IN SARCOMA | FOUNDATION MEDICINE, INC. (US) | 2025-04-24 | — | — | US | claimed |
| US-12274699-B2 | Methods of treating cholangiocarcinoma | FOUNDATION MEDICINE, INC. (US) | 2025-04-15 | — | — | US | claimed |
| EP-4423302-A2 | NOVEL KINASE FUSIONS DETECTED BY LIQUID BIOPSY | Foundation Medicine, Inc. (US) | 2024-09-04 | — | — | EP | claimed |
| US-20240287616-A1 | METHODS OF DETECTING NTRK FUSION PROTEINS | STRATA ONCOLOGY INC (US) | 2024-08-29 | — | — | US | claimed |
| CN-118414439-A | Novel kinase fusion by liquid biopsy | 基金会医学公司 | 2024-07-30 | — | — | CN | claimed |
| EP-4399330-A1 | GENE FUSIONS IN SARCOMA | Foundation Medicine, Inc. (US) | 2024-07-17 | — | — | EP | claimed |
| US-20240228552-A9 | NANOPORE TWEEZER APPROACH FOR PROTEIN KINASE ALLOSTERIC DRUG SCREENING | UNIVERSITY OF MASSACHUSETTS | 2024-07-11 | — | — | US | claimed |
| US-20240132551-A1 | NANOPORE TWEEZER APPROACH FOR PROTEIN KINASE ALLOSTERIC DRUG SCREENING | UNIV MASSACHUSETTS (US) | 2024-04-25 | — | — | US | claimed |
| EP-4355917-A1 | METHODS OF DETECTING NTRK FUSION PROTEINS | Strata Oncology, Inc. (US) | 2024-04-24 | — | — | EP | claimed |
| US-11771698-B2 | Methods of treating cholangiocarcinoma | FOUNDATION MEDICINE, INC. (US) | 2023-10-03 | — | — | US | claimed |
| EP-2914622-B1 | NOVEL FUSION MOLECULES AND USES THEREOF | FOUND MEDICINE INC (US) | 2023-06-07 | — | — | EP | claimed |
| EP-2914621-B1 | NOVEL NTRK1 FUSION MOLECULES AND USES THEREOF | FOUND MEDICINE INC (US) | 2023-06-07 | — | — | EP | claimed |
| WO-2023077104-A2 | NOVEL KINASE FUSIONS DETECTED BY LIQUID BIOPSY | FOUNDATION MEDICINE, INC. (US) | 2023-05-04 | — | — | WO | claimed |
| WO-2023039539-A1 | GENE FUSIONS IN SARCOMA | FOUNDATION MEDICINE, INC. (US) | 2023-03-16 | — | — | WO | claimed |
| US-11578372-B2 | NTRK1 fusion molecules and uses thereof | FOUNDATION MEDICINE, INC. (US) | 2023-02-14 | — | — | US | claimed |
| WO-2022266551-A1 | METHODS OF DETECTING NTRK FUSION PROTEINS | Strata Oncology, Inc. (US) | 2022-12-22 | — | — | WO | claimed |
| WO-2022225995-A1 | METHODS AND SYSTEMS FOR GENE ALTERATION PREDICTION FROM PATHOLOGY SLIDE IMAGES | F. HOFFMANN-LA ROCHE AG (CH) | 2022-10-27 | — | — | WO | claimed |
| US-20220243280-A1 | NTRK FUSION MOLECULES AND USES THEREOF | FOUNDATION MEDICINE, INC. (US) | 2022-08-04 | — | — | US | claimed |
| EP-3980563-A2 | NTRK FUSION MOLECULES AND USES THEREOF | Foundation Medicine, Inc. (US) | 2022-04-13 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11578372-B2 | NTRK1 fusion molecules and uses thereof | NTRK1, NTRK3, NTRK2 | NTRK1 1/4885JAK2 2623/4885AURKA 810/4885 |
| US-20220243280-A1 | NTRK FUSION MOLECULES AND USES THEREOF | NTRK1, NTRK3, NTRK2 | NTRK1 1/4885JAK2 2213/4885AURKA 1025/4885 |
| US-12274699-B2 | Methods of treating cholangiocarcinoma | HCCS, PNLIP, LIPA | NTRK1 2894/4885JAK2 1308/4885AURKA 766/4885 |
| US-11771698-B2 | Methods of treating cholangiocarcinoma | HCCS, PNLIP, LIPA | NTRK1 2894/4885JAK2 1308/4885AURKA 766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.